Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics
May 8th, 2009
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that the European Patent Office (EPO) has issued a notification of intent to grant for a patent (EP1309726) in the Tuschl I patent series. The new patent is the first to be granted in the European Union (EU) from the Tuschl I patent series, and includes 19 claims broadly covering the use of double stranded RNAs (dsRNAs) for RNAi. This new patent grant extends the scope and breadth of Alnylam’s fundamental intellectual property estate that comprises numerous issued or granted patents and a large number of pending patent applications that together broadly cover RNAi therapeutics, including small...
Source: Health Business Week (2009-05-08)
|
